open access

Vol 8, No 4 (2019)
Case reports
Published online: 2019-09-19
Get Citation

Clinical improvement of diabetes mellitus type 1 by b-D-mannuronic acid (M2000) in a breast cancer patient — as a case report

Sarvenaz Kashefi, Ramesh Omranipour, Habibollah Mahmoodzadeh, Hamid Ahmadi, Abbas Mirshafiey
DOI: 10.5603/DK.2019.0018
·
Clinical Diabetology 2019;8(4):227-229.

open access

Vol 8, No 4 (2019)
Case reports
Published online: 2019-09-19

Abstract

A 56 years old female with breast cancer (BC) and poor controlled diabetes mellitus type 1 (DM1) which has registered in a clinical trial for assessment of thera­peutic efficacy of b-D-mannuronic acid (M2000) on pre-surgical BC patients is described in this case report. After receiving M2000, the patient was followed for 9 weeks. During this period, cancer mass details, fast­ing blood glucose (FBG) levels, 2-hour post-prandial blood glucose (2HPP), blood uric acid (BUA) level and urine analysis (UA) were continuously controlled. After 9 weeks of treatment with M2000, her FBG, BUA and UA decreased significantly. This finding was exactly in accordance with our published experimental data about the anti-diabetic effect of M2000 in an animal model. Therefore, it might be concluded that M2000 is probably able to improve DM1 by reducing FBG level, BUA level, glycosuria, ketonuria and proteinuria.

Abstract

A 56 years old female with breast cancer (BC) and poor controlled diabetes mellitus type 1 (DM1) which has registered in a clinical trial for assessment of thera­peutic efficacy of b-D-mannuronic acid (M2000) on pre-surgical BC patients is described in this case report. After receiving M2000, the patient was followed for 9 weeks. During this period, cancer mass details, fast­ing blood glucose (FBG) levels, 2-hour post-prandial blood glucose (2HPP), blood uric acid (BUA) level and urine analysis (UA) were continuously controlled. After 9 weeks of treatment with M2000, her FBG, BUA and UA decreased significantly. This finding was exactly in accordance with our published experimental data about the anti-diabetic effect of M2000 in an animal model. Therefore, it might be concluded that M2000 is probably able to improve DM1 by reducing FBG level, BUA level, glycosuria, ketonuria and proteinuria.

Get Citation

Keywords

b-D-mannuronic acid; M2000; breast cancer; diabetes mellitus; NSAID

About this article
Title

Clinical improvement of diabetes mellitus type 1 by b-D-mannuronic acid (M2000) in a breast cancer patient — as a case report

Journal

Clinical Diabetology

Issue

Vol 8, No 4 (2019)

Pages

227-229

Published online

2019-09-19

DOI

10.5603/DK.2019.0018

Bibliographic record

Clinical Diabetology 2019;8(4):227-229.

Keywords

b-D-mannuronic acid
M2000
breast cancer
diabetes mellitus
NSAID

Authors

Sarvenaz Kashefi
Ramesh Omranipour
Habibollah Mahmoodzadeh
Hamid Ahmadi
Abbas Mirshafiey

References (10)
  1. Zhao XB, Ren GS. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2016; 95(49): e5602.
  2. Xu CX, Zhu HH, Zhu YM. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes. 2014; 5(3): 372–380.
  3. Fattahi MJ, Abdollahi M, Agha Mohammadi A, et al. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol. 2015; 37(6): 535–540.
  4. Mirshafiey A, Taeb M, Mortazavi-Jahromi SS, et al. Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. Pharmacol Rep. 2017; 69(5): 1067–1072.
  5. Mirshafiey A, Cuzzocrea S, Rehm BHA, et al. M2000: a revolution in pharmacology. Med Sci Monit. 2005; 11(8): PI53–PI63.
  6. Hosseini F, Hassannia H, Mahdian-Shakib A, et al. Targeting of crosstalk between tumor and tumor microenvironment by β-D mannuronic acid (M2000) in murine breast cancer model. Cancer Med. 2017; 6(3): 640–650.
  7. Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012; 23(6): 967–981.
  8. M Farahani M, Motevaseli E, Maghsood F, et al. Anti-inflammatory property of β-D-Mannuronic acid (M2000) on expression and activity of matrix metalloproteinase-2 and -9 through CD147 molecule in phorbol myristate acetate-differentiated THP-1 cells. Iran J Allergy Asthma Immunol. 2017; 16(5): 443–451.
  9. Mortazavi-Jahromi SS, Alizadeh S, Javanbakht MH, et al. Anti-diabetic effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model. Arch Physiol Biochem. 2018 [Epub ahead of print]: 1–6.
  10. Mortazavi-Jahromi SS, Alizadeh S, Javanbakht MH, et al. Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model. Immunopharmacol Immunotoxicol. 2018; 40(4): 284–289.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl